Indication
Gestational Trophoblastic Neoplasia
5 clinical trials
2 products
4 drugs
Clinical trial
Efficacy and Safety of Toripalimab Plus Actinomycin-D as Fist-Line Treatment in Patients With Gestational Trophoblastic Neoplasia With FIGO Score 7: A Single-Arm, Multicenter, Phase II TrialStatus: Not yet recruiting, Estimated PCD: 2025-08-01
Drug
PD-1 antibodyProduct
Actinomycin-DClinical trial
Efficacy and Safety of Actinomycin-D With or Without Toripalimab as Fist-Line Treatment in Patients With Gestational Trophoblastic Neoplasia With FIGO Score 5-6: A Multicenter, Open-label, Randomized Controlled TrialStatus: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Feasibility Window Study of Pembrolizumab Prior to Second Evacuation for Post-molar Gestational Trophoblastic NeoplasiaStatus: Recruiting, Estimated PCD: 2026-02-01
Drug
mFOLFOX6Clinical trial
A Prospective,Multicenter,Randomized Trial of Biweekly Single-dose Actinomycin-D Versus Multi-day Methotrexate Protocol for the Treatment of Low-risk Gestational Trophoblastic NeoplasiaStatus: Recruiting, Estimated PCD: 2024-12-01
Drug
DocetaxelProduct
DactinomycinClinical trial
Phase 2 Single Agent Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia (GTN)Status: Withdrawn, Estimated PCD: 2026-12-01
Drug
Atezolizumab